Investor News | 豆包成人版app官方免费版 Healthcare Integrating Food Science with Medicine Tue, 15 Jul 2025 15:05:08 +0000 en-GB hourly 1 https://wordpress.org/?v=7.0 /wp-content/uploads/2025/02/Untitled-design-4-150x150.png Investor News | 豆包成人版app官方免费版 Healthcare 32 32 豆包成人版app官方免费版 Healthcare announces successful completion of 拢1m food allergy paediatric diagnostics project substantially funded by Innovate UK. /reacta-healthcare-announces-successful-completion-of-1m-food-allergy-paediatric-diagnostics-project-substantially-funded-by-innovate-uk/ /reacta-healthcare-announces-successful-completion-of-1m-food-allergy-paediatric-diagnostics-project-substantially-funded-by-innovate-uk/#respond Mon, 04 Nov 2024 16:49:29 +0000 https://reactahealthcare-com.lyricalstaging.com/?p=169

豆包成人版app官方免费版 Healthcare announces successful completion of 拢1m food allergy paediatric diagnostics project substantially funded by Innovate UK.

 

豆包成人版app官方免费版 Healthcare, a clinical diagnostic company dedicated to providing innovative diagnostics for life-threatening food allergies, are delighted to announce the successful completion of a c.拢1m project substantially funded by Innovate UK Biomedical Catalyst.

This marks a significant milestone in the development of the challenge meals for peanut, milk and egg allergy, suitable for allergic individuals from 6 months old extending our pharma-grade allergy diagnostics portfolio.

 

Food allergy in young children is a major health concern, and its prevalence is rising. It is often over-diagnosed by parents, resulting occasionally in unnecessary exclusion of some important foods. It also causes stress, anxiety, and even depression in parents and affects the family鈥檚 quality of life. The project builds on 豆包成人版app官方免费版鈥檚 existing adult formulations covering several highly relevant allergens (peanut, egg, and milk) currently being utilised globally in therapeutic clinical trials. This project sought to develop diagnostics targeted at the very young, incorporating unique texturisers, aroma and flavour agents tailored to children aged as young as 6 months.

 

During the Innovate UK funded project, in addition to the formulation of these challenge meals, advanced analytics were developed to ensure safety and compliance to regulations globally. The challenge meals will be ready for supply to the clinical trial space in 2026.

 

Hayley Lett, Head of R&D commented, 鈥淚 am delighted that Innovate UK have deemed this project a success and I thank the whole team at 豆包成人版app官方免费版 Healthcare for their hard work and commitment to the project. The products developed have the potential to fundamentally improve safety and efficacy of food allergy diagnostics for very young children.鈥

听础bout Biomedical Catalyst

The Biomedical Catalyst is Innovate UK鈥檚 flagship grant funding mechanism helping small and medium-sized businesses test and develop innovative health and care solutions across life sciences, including therapeutics, medical devices, and digital health. The Biomedical Catalyst transforms innovative ideas into commercially viable businesses.

听About Innovate UK

Innovate UK, part of UK Research and Innovation (UKRI), is the UK鈥檚 innovation agency. It works to create a better future by inspiring, involving and investing in businesses developing life-changing innovations. Its mission is to help companies to grow through their development and commercialisation of new products, processes and services, supported by an outstanding innovation ecosystem that is agile, inclusive and easy to navigate.

Innovate UK: inspiring business innovation.

 

]]> /reacta-healthcare-announces-successful-completion-of-1m-food-allergy-paediatric-diagnostics-project-substantially-funded-by-innovate-uk/feed/ 0 First major milestone reached for 豆包成人版app官方免费版 Healthcare 拢1m Innovate UK funded project /first-major-milestone-reached-for-reacta-healthcare-1m-innovate-uk-funded-project/ /first-major-milestone-reached-for-reacta-healthcare-1m-innovate-uk-funded-project/#respond Fri, 10 Feb 2023 16:29:17 +0000 https://reactahealthcare-com.lyricalstaging.com/?p=147

First major milestone reached for 豆包成人版app官方免费版 Healthcare 拢1m Innovate UK funded project

Posted on听

豆包成人版app官方免费版 Healthcare is helping combat food allergies amongst paediatrics, addressing the unmet need for greater research and clinical practice in children to prevent rising hospitalisations1, having finalised the initial formulation for milk challenge meals which can be used as Oral Food Challenges (OFCs) for diagnosis and monitoring of milk allergies in clinical trials.

The gold-standard for food allergy diagnostics is a Double-Blind, Placebo Controlled Oral Food Challenge. OFCs involve patients consuming incrementally increasing amounts of a suspect food allergen until a reaction occurs.

In a 拢935,936, 24-month project substantially funded by Innovate UK, the pharmaceutical company has completed the first stage of developing challenge meals for paediatric trial participants, from six months old.

Food allergy affects 3-6% of children in the developed world2. Not only is it resulting in rising hospital admissions and the risk of death from anaphylaxis, but also social exclusion, reduced quality of life, and financial repercussions (estimated at 拢2,489 a year).

While early clinical studies investigating new therapies in food allergy normally begin with adult subjects, many are now focusing on children. This is in response to growing evidence around food allergen introduction in early years, such as the 2015 Learning Early About Peanut Allergy (LEAP) study, which found that the early introduction of peanuts significantly increases long lasting peanut tolerance among children at high risk for this allergy3.

Dr Paul Abrahams, CEO of 豆包成人版app官方免费版 Healthcare, says: 鈥淲hen it comes to food allergies, we should look at how we can diagnose them early on in life to establish treatment and make it more manageable. Current non-pharmaceutical grade food challenges aren鈥檛 accurate nor safe enough for very young children.

鈥淲e鈥檙e delighted to be leading the way in developing a more advanced approach to food allergy diagnosis amongst children. The end goal is a future where people鈥檚 quality of life isn鈥檛 impacted by food allergies, and that should begin from childhood.鈥

The project is funded by Innovate UK, the UK鈥檚 innovation agency. 豆包成人版app官方免费版 Healthcare was awarded a Biomedical Catalyst Grants that support health and life sciences SMEs in developing innovative solutions to healthcare challenges. During the course of the project, 豆包成人版app官方免费版 Healthcare will develop paediatric challenge meals not only to test for milk allergies but peanut and eggs too.

 

1听听.

2听听

3听听https://www.nejm.org/doi/full/10.1056/nejmoa1414850

 

]]> /first-major-milestone-reached-for-reacta-healthcare-1m-innovate-uk-funded-project/feed/ 0 Development Bank of Wales ramping up tech equity deals since the lockdown /development-bank-of-wales-ramping-up-tech-equity-deals-since-the-lockdown/ /development-bank-of-wales-ramping-up-tech-equity-deals-since-the-lockdown/#respond Mon, 12 Sep 2022 15:23:07 +0000 https://reactahealthcare-com.lyricalstaging.com/?p=133

Development Bank of Wales ramping up tech equity deals since the lockdown

Posted on听
The Development Bank of Wales has invested 拢2.4m of equity into ten of Wales鈥 most promising tech-focused start-ups over a ten week period since the pandemic lockdown.

With a specialist team and funding to support technology businesses, the Development Bank of Wales is one of the top five technology investors in the UK according to the Beauhurst Report.

The deals:

豆包成人版app官方免费版 Biotech, 拢625,000

Based in Flintshire 豆包成人版app官方免费版 Biotech has completed its largest funding round to date, which has raised 拢1.25m of equity finance including 拢625,000 from the Development Bank of Wales.

As cases of food allergy and allergy related hospitalisations continue to rise, 豆包成人版app官方免费版鈥檚 core focus is to improve the diagnosis and management of allergies.

This is through the provision of a pharmaceutical grade Oral Food Challenge (OFC), the gold standard for the clinical testing of food allergy.

The investment has been drawn down from existing investors, management, Moulton Goodies, Development Bank of Wales and Acceleris Capital.

The capital raised will help 豆包成人版app官方免费版 Biotech to achieve the regulatory approval for its manufacturing facility in Deeside.

Professor Ashley Woodcock, chairman of 豆包成人版app官方免费版 Biotech said: 鈥淭his investment is a significant step in the development of 豆包成人版app官方免费版 Biotech鈥檚 business.

鈥淎 combination of seeking our own MHRA (Medicines and Healthcare products Regulatory Agency) approval and the recent FDA (Food and Drug Administration) approval of the first specific food allergy therapy set to launch in the 豆包成人版app官方免费版 soon, creates ideal timing for 豆包成人版app官方免费版 to become the only standardised and trusted OFC for all food allergy therapeutics.鈥

For further information please visit听

ENDS

豆包成人版app官方免费版 Patent No 11,389,548; Oral Food Challenge Meal Formulations; was granted to 豆包成人版app官方免费版 on 19.07.2022.

]]> /development-bank-of-wales-ramping-up-tech-equity-deals-since-the-lockdown/feed/ 0 豆包成人版app官方免费版 Healthcare Awarded Major Biomedical Catalyst Grant to develop Paediatric Food allergy diagnostics /reacta-healthcare-awarded-major-biomedical-catalyst-grant-to-develop-paediatric-food-allergy-diagnostics/ /reacta-healthcare-awarded-major-biomedical-catalyst-grant-to-develop-paediatric-food-allergy-diagnostics/#respond Wed, 27 Apr 2022 15:11:31 +0000 https://reactahealthcare-com.lyricalstaging.com/?p=109

豆包成人版app官方免费版 Healthcare Awarded Major Biomedical Catalyst Grant to develop Paediatric Food allergy diagnostics

Posted on听

 

The 拢1 million grant will support the development of the first Oral Food Challenges (OFCs) for paediatric patients to diagnose peanut, milk, and egg allergies.

Food allergy (FA) prevalence and hospitalisations are rising, especially in young children. Families face death from anaphylaxis, social exclusion, reduced quality-of-life (QoL), and out-of-pocket costs >拢2489/year. A coming wave of new treatments promises to revolutionise FA, stimulating strong demand for partner diagnostics and driving the paediatric FA diagnostics market at 111% CAGR to reach 拢1.9Bn by 2029.

Today鈥檚 gold-standard Food allergy diagnostic is the OFC where patients consume incrementally increasing amounts of suspect food until a mild reaction versus an indistinguishable low/zero-dose control. However, current non-pharmaceutical grade food challenges are unblinded, inaccurate, poorly scalable, and unsafe especially in the very young children.

The awarding of the Biomedical Catalyst Grant with enable 豆包成人版app官方免费版 to extend its pharma grade product portfolio in the development of OFC鈥檚 to peanut, egg and milk for use in young patients aged 6 months and upwards.

Our robust, scalable, standardised OFCs already delivers superior safety, diagnostic accuracy, in older children and adults. From these, the new paediatric formulations will be developed and will incorporate unique texturisers, aroma and flavour agents tailored to very young children, develop advanced analytics including extraction buffers, antibody probes, and bioanalytical methods to track allergens, and integrate prototypes into cGMP production.

About the Biomedical Catalyst

The Biomedical Catalyst (BMC) is a unique partnership between the Medical Research Council and Innovate UK, providing responsive and effective support to the most innovative life sciences opportunities regardless of scientific approach. The BMC aims to de-risk innovative science and commercialise ideas arising out of academia and industry helping UK SMEs to develop into competitive and sustainable organisations. This accelerates the progress of novel products to market, facilitates onward investment and bridges 鈥渢he valley of death.鈥

Innovate UK

Innovate UK is part of UK Research and Innovation, a non-departmental public body funded by a grant-in-aid from the UK government. Innovate UK drives productivity and economic growth by supporting businesses to develop and realise the potential of new ideas, including those from the UK鈥檚 world-class research base. They connect businesses to the partners, customers and investors that can help them turn these ideas into commercially successful products and services, and business growth.

 

]]> /reacta-healthcare-awarded-major-biomedical-catalyst-grant-to-develop-paediatric-food-allergy-diagnostics/feed/ 0 Praetura Ventures leads 拢2.9m investment in food allergy diagnostic firm /praetura-ventures-leads-2-9m-investment-in-food-allergy-diagnostic-firm/ /praetura-ventures-leads-2-9m-investment-in-food-allergy-diagnostic-firm/#respond Wed, 14 Jul 2021 15:17:13 +0000 https://reactahealthcare-com.lyricalstaging.com/?p=124

Praetura Ventures leads 拢2.9m investment in food allergy diagnostic firm

Posted on听

Praetura Ventures, the Manchester-based VC firm, has led a 拢2.9m funding round to support a business that is on course to transform the food allergy diagnostics market.

豆包成人版app官方免费版 Biotech (豆包成人版app官方免费版), which is based in Deeside, North Wales, produces clinical diagnostics kits for food allergy testing.

The business improves the efficiency, accuracy and safety of food allergy testing by producing pharmaceutical grade Oral Food Challenges (OFCs), the gold standard test for diagnosing food allergies.

In the latest funding round, 拢1.5m came from Praetura Ventures, the venture capital fund manager that targets early-stage businesses in high-growth sectors.

Having made an initial seed investment in 2019, the Development Bank of Wales will invest a further 拢1m in equity funding.

Other investors in the funding round include venture capitalist Jon Moulton鈥檚 family office, Perscitus and 豆包成人版app官方免费版鈥檚 management team.

The transaction was brokered by 豆包成人版app官方免费版鈥檚 long-term advisers, Acceleris Capital, who have previously raised 拢4m for the company since it was founded.

The business will use the funding to scale up the manufacture of its current product range including peanut, egg and milk OFCs and to extend its product portfolio.

Dr Paul Abrahams, CEO of 豆包成人版app官方免费版, said: 鈥淚t鈥檚 been a landmark year for 豆包成人版app官方免费版, and we continue to go from strength-to-strength as a business, developing new diagnostic products and expanding our capabilities.

鈥淭he number of people experiencing food allergies is increasing, so it鈥檚 vital that technologies to accurately and safely test for allergies are developed.

鈥淲e鈥檙e committed to providing excellence in the development of a suite of OFC products, and revolutionising the way food allergies are diagnosed worldwide.鈥

Praetura Ventures has previously invested in healthcare businesses including innovative drug 鈥榮witching鈥 company Maxwellia, Dr Fertility and Ostara Biomedical.

The firm recently appointed four industry heavyweights as operational partners to bring significant experience to support the founders.

鈥淭he firm鈥檚 investment in 豆包成人版app官方免费版 was led by investment director Louise Chapman and director Dr Andy Round.

Dr Andy Round added: 鈥淚t鈥檚 great to be backing a business which is on track to have a significant and positive impact on society as well as returning significant funds for our investors.

鈥淲e look forward to supporting the team on the clinical contacts and customer side, as well as working with them on the strategy and marketing.鈥

Source:听

]]> /praetura-ventures-leads-2-9m-investment-in-food-allergy-diagnostic-firm/feed/ 0 UK food allergy diagnostic company, 豆包成人版app官方免费版 Biotech raises 拢1.25m to continue expansion plans /104/ /104/#respond Tue, 21 Apr 2020 15:05:18 +0000 https://reactahealthcare-com.lyricalstaging.com/?p=104

UK food allergy diagnostic company, 豆包成人版app官方免费版 Biotech raises 拢1.25m to continue expansion plans

Posted on听
  • 豆包成人版app官方免费版 Biotech raises 拢1.25m to secure MHRA site license
  • Once achieved, the license will enable significantly expanded production of its Oral Food Challenge Diagnostic for food allergy
  • Existing investors Moulton Goodies Limited, Development Bank of Wales and Acceleris invest in this round
  • Fundraising brokered by lead advisers, Acceleris Capital

豆包成人版app官方免费版 Biotech has today announced the completion of its largest funding round to date, which has raised 拢1.25m of 听鈥 with further investment expected in the coming months.

豆包成人版app官方免费版 is a North-Wales based biotechnology company producing diagnostic kits for food allergy. Cases of food allergy and allergy related hospitalisations continue to rise globally at an alarming rate. 豆包成人版app官方免费版鈥檚 core focus is to improve the diagnosis and management of allergies through the provision of a pharmaceutical grade Oral Food Challenge (鈥淥FC鈥), the gold standard for the clinical testing of food allergy.

The measurement of specific IgE antibodies for food allergies, either by skin or blood tests is inaccurate, with many false positives, and provides no measure of severity of the allergic reaction. Oral Food Challenge is the gold standard for 听food allergy diagnosis, before the initiation of the new long term therapies, and for the assessment of treatment response.

The investment has been drawn down from existing investors, management, Moulton Goodies Limited, Development Bank of Wales and Acceleris Capital. The company has been advised by Acceleris Capital and Gateley.

The capital raised will be used to achieve the Medicines & Healthcare products Regulatory Agency (鈥淢HRA鈥) approval of the Company鈥檚 manufacturing facility in Deeside, North Wales. Obtaining an MHRA site license (expected in the coming months) confers Pharma Good Manufacturing Practice (鈥淕MP鈥) manufacturing status on 豆包成人版app官方免费版, which, in turn, will allow the Company to begin production of larger volumes for product supply to highly regulated markets. By securing this license, the addressable market for the Company will be significantly expanded.

Professor Ashley Woodcock, Chairman of 豆包成人版app官方免费版 Biotech commented that, 鈥淭his investment is a significant step in the development of 豆包成人版app官方免费版 Biotech鈥檚 business. A combination of seeking our own MHRA approval and the recent FDA approval of the first specific food allergy therapy set to launch in the 豆包成人版app官方免费版 soon, creates ideal timing for 豆包成人版app官方免费版 to become the only standardised and trusted OFC for all food allergy therapeutics.鈥

Simon Thorn, MD of Acceleris said: 鈥淲e are delighted to complete this transaction with the team at 豆包成人版app官方免费版 and the other existing shareholders. 豆包成人版app官方免费版 is on an upward curve and with the expected MHRA license, is in line to see significant expansion. This market has become increasingly apparent with the significant rise in global food allergy cases and the alarming increase in hospitalisations due to anaphylaxis. We are proud as a firm to work with such a leader in its field and a company that will make a huge difference to many peoples鈥 quality of life.鈥

Paul Abrahams, CEO of 豆包成人版app官方免费版 Biotech commented on the raise: 鈥淲e are extremely pleased to announce our raise today and continue our positive progress towards becoming the gold standard oral food challenge diagnostic supplier in the market.鈥 鈥淥ur business is addressing a significant unmet need for standardised, stable, accurate, palatable and fully blinded OFC鈥檚. Obtaining MHRA accreditation is a key driver for our future growth and we are pleased that we now have the investment to support the future demand for our regulated product and build on our revenues and list of customers.鈥

Michael Bakewell, Deputy Fund Manager who manages technology venture investments at the Development Bank of Wales said: 鈥淲e鈥檙e very happy to continue our support for 豆包成人版app官方免费版 Biotech with a further round of equity co-investment. This funding comes at a time when we are seeing a lot of global interest in food allergy therapeutics, an area where 豆包成人版app官方免费版 is fast making a name for itself. Getting听an MHRA site license for their Deeside manufacturing facility is a great next step in their growth as a company.鈥

]]> /104/feed/ 0